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ABSTRACT Phosducin is a soluble phosphoprotein found
in retinal photoreceptor cells and in the pineal gland. It binds
to the fty subunits of guanine nucleotide-binding proteins (G
proteins) (GP,y) and may regulate G-protein function. In this
study, the ability of specific regions of phosducin to bind GPY
was characterized. A series of deletion mutants were made in
bovine phosducin. They were tested in cotransfection assays
for their ability to inhibit Gf,y-mediated phospholipase C P82
isoform activation. Overexpression of the N-terminal half of
phosducin showed inhibition, whereas overexpression of the
C-terminal half did not. The first 63 amino acid residues were
required for inhibition. A tryptophan-to-valine substitution at
residue 29, which is part of a well conserved 11-amino acid
sequence, severely impaired phosducin inhibitory function.
Glutathione S-transferase-phosducin fusion proteins were
expressed in Escherichia coli to study phosducin-GPy inter-
action in vitro. The N-terminal 63-amino acid fragment was
able to bind to GP8y. In contrast, the C-terminal half failed to
bind to Gp'y. The substitution mutants showed little or no
binding. Furthermore, direct measurements of interaction
between G8,Py and fragments of phosducin, using surface
plasmon resonance technology, confirmed the assignment of
binding activity to the 63-amino acid fragment and the
importance of the tryptophan residue.
Guanine nucleotide-binding proteins (G proteins) mediate signal
transduction across cellular membranes (1, 2). Activated cell
surface receptors stimulate the binding ofGTP to the a subunits
of target G proteins and GTP binding promotes dissociation of
G protein 13Py subunits (GI3y), allowing the a and f3y subunits to
interact with a variety of effector molecules. Recent studies have
revealed new and independent functions for the f3y subunits (3).
In addition to regulation of phospholipase C activity (4, 5), GfB3y
was also found to be involved in modulation of the activities of
adenylyl cyclase (6), potassium channels (7-9), and kinases,
including ,3-adrenergic receptor kinase (PARK) (10, 11), mito-
gen-activated protein kinase (12), and phosphatidylinositol-3-
kinase (13). By interacting with cellular molecules other than the
a subunits, Gf3,y contributes to the complex regulation of signal
transducing circuits.
Phosducin (Phd) is a 33-kDa soluble phosphoprotein iden-
tified in vertebrate photoreceptor cells (14, 15) and the pineal
gland (16, 17). It forms complexes with the 13,y subunits of
transducin (14), which belong to the G-protein family. Binding
of Phd to G,I3y is regulated by the phosphorylation state of Phd.
Phd can be phosphorylated by protein kinase A (18), and upon
phosphorylation the affinity for Gf3y decreases (19). Inside the
cell, Phd may compete with other Gf3y targets for Gf3y
binding, and thus it may be involved in regulation of many
biological processes. It has been suggested that Phd, which is
relatively abundant in the rod photoreceptor cells, regulates
the amount of fly subunits available to interact with the a
subunits of transducin to form heterotrimers and thus can
function as a negative regulator of the cGMP cascade in the
visual system. Addition of Phd to photolysed rod outer seg-
ment membranes reduces the GTP hydrolysis activity of
transducin and the subsequent activation of the cGMP phos-
phodiesterase (20). Phd also inhibits receptor phosphorylation
by ,BARK; it presumably prevents I3ARK from translocating to
the membranes by scavenging GP3y. Phosphorylation of Phd
attenuates this inhibition (21). Phd was also found to inhibit the
intrinsic GTPase activity of several G proteins, including Gs,
Go, and Gi (19). In addition, direct binding of Phd to Gg3y
could also lead to other Phd functions that have not yet been
identified. It is therefore important to further investigate
Phd-Go3y interaction.
In this study, a series of specific deletion and amino acid
substitution mutations were made in bovine Phd. Their ability to
bind to Gf3y was tested by inhibition of Gf3y-mediated phospho-
lipase C (32 isoform (PLC/32) activation in the cotransfection assay
and by direct in vitro binding assays. The Gf3y binding activity was
localized to the first 63 amino acid residues of Phd.
MATERIALS AND METHODS
Plasmids for COS-7 Cell Transfection. All of the Phd
deletion mutants were constructed by PCR with the plasmid
pPDTSC (kindly provided by Rehwa Ho Lee, University of
California, Los Angeles) as the template. A sequence encoding
the 9-amino acid epitope tag YPYDVPDYA, derived from
human influenza virus hemagglutinin (HA tag) (22), was
introduced into the C terminus of each construct during PCR.
PCR products were cloned between Cla I andXho I sites of the
pCIS vector (23) for transfection in COS-7 cells. A point
mutation changing tryptophan to valine at position 29 was
introduced into the wild-type cDNA by the double-strand
mutagenesis strategy (24). All constructs were confirmed by
DNA sequencing.
Expression plasmids for human PLCf32 and bovine G31 and
G'y1 have been described (5).
Transfection. COS-7 cells were seeded at a density of 1 x 105
cells per well in 12-well dishes 1 day before transfection. One
microgram of DNA was used in each well. The molar ratio of
DNA used for transfection of PLCI32, GP1,, Gyl, and Phd was
1. Wherever necessary a plasmid expressing the ,B-galactosi-
dase gene under the control of the cytomegalovirus promoter
was cotransfected to keep the total amount of DNA constant;
0.5 ml of Opti-MEM (GIBCO/BRL) containing 1 jig ofDNA
along with 5 Al of LipofectAmine (GIBCO/BRL) was added
to each well. Five hours later, the medium was replaced with
1 ml of Dulbecco's modified Eagle's medium containing 10%
fetal calf serum. Transfected cells were labeled the next day
with 10 ,uCi of myo-[2-3H]inositol per ml (NEN) (1 Ci = 37
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GBq) in 0.4 ml of inositol-free medium containing 10%
dialyzed fetal calf serum. After 24 hr, the levels of [3H]inositol
phosphate were determined as described (5).
SDS/PAGE, Western Blot Analysis, and Antiserum. Gel
electrophoresis was carried out in SDS/12% polyacrylamide
slab gels according to Laemmli (25). The proteins were then
transferred to nitrocellulose membranes at 100 V for 1 hr in
25 mM Tris/192 mM glycine/20% (vol/vol) methanol and
subsequently detected by specific antibodies with the ECL
Western blotting system (Amersham). The Gf31 antibody was
raised against the N-terminal 14 amino acid residues of bovine
Go31. The anti-HA tag antiserum HAll was purchased from
Berkeley Antibody (Richmond, CA).
In Vitro Binding of Gj3y to Glutathione S-Transferase
(GST)-Phd Fusion Proteins. Phd wild-type and mutant
cDNAs were placed in-frame downstream of the GST cDNA
in the pGEX-3X vector (Pharmacia) using the BamHI and
EcoRI sites. The fusion proteins GST-Phdl-245 and GST-
Phdl-63 contain full-length Phd and amino acid residues 1-63
of Phd, respectively, with the first 2 amino acid residues
converted to proline and glycine. The fusion protein GST-
Phdll2-245 contains amino acid residues 112-245. Plasmids
were transformed into Escherichia coli stain DH1OB or BL21.
Expression of the GST fusion proteins was induced with
isopropyl, P-D-thiogalactoside at a final concentration of 1 mM
for 2 hr after the A6co reading of the culture reached 0.8. The
cells were pelleted and resuspended in phosphate-buffered
saline (PBS) containing 1% Triton X-100 followed by mild
sonication. The soluble fractions were incubated with the
glutathione Sepharose 4B beads (Pharmacia) at 4°C for 2 hr
followed by washing three times with PBS.
For affinity chromatography, purified G3-y, which was
prepared as described by Bigay and Chabre (26) from the
bovine retina and diluted in PBS containing 0.01% lubrol, was
then added. After the GST fusion protein and GP3y were
incubated for another 2 hr at 4°C, the beads were washed four
times with PBS containing 0.01% lubrol. Finally, the beads
were eluted with the SDS/PAGE sample buffer and the
proteins were separated on a SDS/12% polyacrylamide gel
and analyzed by Western blotting.
For analysis of Phd-GP3y interactions using a surface plas-
mon resonance (SPR) biosensor, purified Gf3y was biotiny-
lated with NHS-LC-biotin (Pierce) and coupled to the sensor
surface of Pharmacia biosensor chip SA5 with covalently
immobilized streptavidin. In a standard experiment, 2000 ±
200 resonance units (RU) of Gf3y was attached to the surface.
Binding of the biotinylated GJ3y heterodimer was very stable:
only 1-5 RU of the bound protein dissociated per minute. This
allowed kinetic analysis of the interactions of Go3y with the
recombinant Phd as well as with Ga and P3ARK (V.Z.S.,
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unpublished data). GST-Phd fusion proteins were eluted from
the glutathione Sepharose beads in 50 mM Tris HCl (pH 8.0)
with 10 mM reduced glutathione. Different concentrations of
fusion proteins were flown through the surface with coupled
GJ3y. The running buffer contains 10 mM NaHepes, 120 mM
NaCl, 2.5 mM MgCl2, 0.5 mM EDTA, and 0.01% Tween 20
(pH 7.4). The injections lasted for 8 min at a flow rate of 5
,ul/min. The kinetic analysis of the resulting binding curves
(sensograms) was performed with BLAevaluation software,
Version 2.0 (Pharmacia Biosensor).
RESULTS
The N Terminus of Phd Is Required for Inhibition of
Gfry-Mediated PLCf32 Activation. The Gf1gy1 complex with a
fully modified yl subunit has been shown to activate PLCf32 (4,
5); thus, the presence of Phd may inhibit Gf3y-mediated PLC,32
activation by scavenging G,y. To test this notion, we cotrans-
fected COS-7 cells with bovine Gig, and Gy, subunits, with
human PLCJ32, and with or without bovine Phd. Cells trans-
fected with Go3y and PLC/32 accumulated a higher level of
inositol phosphate than those transfected with Phd along with
Gl,y and PLCP32 (see Fig. 2A). This indicates that the wild-type
Phd inhibits Gf3y-mediated PLCI32 activation. This phenom-
enon was used as an assay system in the following study to
detect interaction between GQ3y and Phd mutants. Several
deletion mutants of bovine Phd (Fig. 1) were prepared by PCR.
The mutants were cotransfected with Gfry and PLC032 into
COS-7 cells and PLC,32 activity was measured. As shown in
Fig. 2A, the mutant that consists of the N-terminal 120
residues (Phdl-120) was able to inhibit 68% of G,3y-mediated
PLCI32 activity, while the mutant that contains the C-terminal
half of Phd extending from residues 112 to 245 (Phdll2-245)
showed no inhibition. This suggests that the Gf3y binding
regions of Phd are located in its N-terminal half. Additional
deletions revealed that the mutant containing the first 63
residues (Phdl-63) was able to inhibit 39% of Gf3y-mediated
PLCI32 activity. The larger residual portion of the protein
(Phd55-245), however, showed little (<8%) inhibition. This
further suggests that the N terminus of Phd plays an important
role in Gl3y binding. It is worth noting that the phosphoryla-
tion site on Phd, Ser-73 (18), is not included in mutant
Phdl-63. Two more deletion mutants were prepared and their
activities confirmed our initial results. The inhibitory activity
of the C-terminal deletion mutant (Phdl-90) fell between the
activities of the previous two mutants (Phdl-63 and Phdl-
120). The N-terminal deletion mutant (Phd88-245) failed to
inhibit PLCf32 activity as predicted by our earlier results (data
not shown). Phd did not show specificity toward different 'y
subunits since it inhibited PLC32 activities stimulated by GP3
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FIG. 1. Summary of Phd mutant constructs and their ability to inhibit Gf3y-mediated PLC032 activation. Solid box, HA tag; numbers, first and
last amino acid residues in each construct; W, tryptophan at position 29; V, valine substitution; +, ability to inhibit; -, inability to inhibit.
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FIG. 2. Deletion mutants. (A) Activities of deletion mutants in the
cotransfection assay. Transfections were done and PLC032 activities
were measured as described. Gf3y-activated PLCf32 activity was set at
100%. Means + SD from at least three experiments are presented.
Numbers indicate first and last amino acid residues in each construct.
wt, Wild type; LacZ, plasmid expressing 13-galactosidase gene. (B)
Western blot analysis using HAll antiserum. COS-7 cells were
transfected as described and lysed in SDS/PAGE sample buffer.
One-twentieth of cell lysate from one well of a 12-well dish was loaded
for the wild-type Phd as the control amount. SDS/polyacrylamide gel
was electroblotted onto nitrocellulose membrane (pore size, 0.45 Jim)(Costar). Lanes: 1, lacZ (20-fold the control amount of cell lysate was
loaded); 2, Phdll2-245 (twice the control amount of cell lysate was
loaded); 3, Phd55-245 (twice the control amount of cell lysate was
loaded); 4, Phd wild type, control; 5, Phdl-120 (20-fold the control
amount of cell lysate was loaded); 6, Phdl-63 (20-fold the control
amount of cell lysate was loaded). Molecular mass standards (kDa) are
marked on the left.
in combinations of various Gy subunits, including Gyj, Gy2,
G,y3, G'y5, and the G-y subunit from the cone photoreceptor
cells (data not shown).
To verify that the differences in the inhibitory effects of
these Phd mutants did not result from differences in their
expression levels in COS-7 cells, Western blotting analysis was
performed. The wild-type and mutant Phd proteins were
labeled at their C terminus with a 9-amino acid epitope tag
sequence, YPYDVPDYA, derived from human influenza
virus HA (HA tag) (22). Insertion of the tag into Phd did not
affect the inhibitory function of Phd on Gfry-mediated PLCI32
activation (data not shown). The anti-HA polyclonal anti-
serum, HAll, which recognizes the 9-amino acid sequence,
was used in the Western blot analysis. As shown in Fig. 2B, the
N-terminal deletion mutants were expressed at higher levels
than the C-terminal deletion mutants. Despite an '20-fold
higher level of expression, the C-terminal portion of Phd was
unable to inhibit PLCf32 activity. We therefore conclude that
the N-terminal part of Phd plays a crucial role in inhibiting the
Gfry-activated function of PLCfB2. Phd and its various mutant
forms have no effects on the basal PLC932 activity (data not
shown). The Western blot experiments using antisera against
GP31 and PLCf32 demonstrated that cotransfection of Phd and
its mutants did not affect the expression levels of recombinant
GP3y and PLCf32 (data not shown).
The Tryptophan Residue Is Important. The first 63 residues
are apparently required for inhibiting Gf3y-mediated PLCj32
activation. In this region, there is an 11-amino acid stretch that
is conserved in all Phd molecules found in different vertebrate
species as well as in the Phd-like protein (27). Within this
11-amino acid sequence resides the only tryptophan residue
found in Phd. Conserved tryptophan residues have been found
in other protein homology motifs, including the pleckstrin
homology (PH) domains (28) and the WD repeats (29). And
the highly conserved tryptophan residue in subdomain 6 of the
PH domain of Bruton tyrosine kinase has been shown to play
a critical role in binding of Gf3y to this kinase (30). Thus, the
tryptophan residue in Phd was replaced with a valine residue
in the wild type (PhdW29V) and in the two C-terminal deletion
mutants (PhdW29V1-120 and PhdW29V1-63) (Fig. 1). As
shown in Fig. 3A, the point mutation severely impaired the
inhibitory ability of Phd. The full-length Phd carrying this
point mutation could inhibit only 17% of GJ38y-activated
PLCI32 activity compared to 93% by the wild type. The point
mutation completely abolished the inhibitory effects when
introduced into the C-terminal deletions (PhdW29V1-120 and
PhdW29V1-63) (Fig. 3A). Western analysis (Fig. 3B) showed
that all of the mutant proteins were expressed at levels that are
equal to or higher than their counterparts without the point
mutation. Thus, the losses of inhibitory effects were not due to
lower levels of protein, suggesting that the tryptophan residue
is critical for the inhibition of G13y-mediated PLCI82 activation.
The First 64-Amino Acid Residue Fragment ofPhd Binds to
Gf3y in Vitro. To obtain more direct evidence for interaction
between Phd and Gf3y, Phd and its mutants were expressed in
E. coli as GST fusion proteins (Fig. 4A). The cDNAs were
cloned into the vector pGEX-3X (Pharmacia). Protein expres-
sion was induced by isopropyl 13-D-thiogalactoside. The soluble
fractions were immobilized on glutathione Sepharose 4B
beads (Pharmacia). Purified Gf3y from the bovine retina was
then incubated with the GST fusion proteins. Gf3y retained by
the beads was detected by Western analysis. As shown in Fig.
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FIG. 3. Tryptophan-to-valine substitution at position 29. (A) Ac-
tivities of mutants in the cotransfection assay. Transfections were done
and PLCf32 activities were measured as described. Gf,ry-activated
PLC32 activity was set at 100%. Means + SD from at least three
experiments are presented. Open and hatched bars, wild type and
mutant counterparts, respectively; numbers, first and last amino acid
residues in each construct. (B) Western blot analysis using HAl1
antiserum. COS-7 cells were transfected as described and lysed in
SDS/PAGE sample buffer. One-twentieth of cell lysate from one well
of a 12-well dish was loaded for full-length constructs (20 times the
amount of cell lysate was loaded for the remaining samples). SDS/
polyacrylamide gel was electroblotted onto nitrocellulose membrane
(pore size, 0.45 ,um). Lanes: 1, lacZ; 2, Phd; 3, PhdW29V; 4, Phdl-120;
5, PhdW29V1-120; 6, Phdl-63; 7, PhdW29V1-63. Molecular mass
standards (kDa) are marked on the right.
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FIG. 4. In vitro binding of GST-Phd fusion proteins and G/3y in
affinity chromatography. Experiments were done as described. (A)
Coomassie blue staining of expressed GST fusion proteins. (B)
Western blot analysis of GST fusion protein and Gfry binding with
anti-fSi antiserum. About 5 ,Ag of fusion protein and 400 ng of purified
Gf^y were used for each sample. Lanes: 1, GST-Phd; 2, GST-Phdl-
63; 3, GST-Phdll2-245; 4, GST-PhdW29V; 5, GST-PhdW29V1-
63. Molecular mass standards (kDa) are marked on the left (A) and
right (B).
4B, wild-type Phd bound to GP,3 very well. The GST fusion
protein containing the first 63 residues of Phd was able to bind
to G,31, as predicted by the results obtained in cotransfection
assays. Its binding affinity for GI3y is apparently lower than the
wild type because lower levels of Go1 were retained. In
contrast, the C-terminal half of Phd was not able to bind to G(31
under the same conditions. In addition, tryptophan-to-valine
substitution in the full length drastically decreased, and this
substitution in the 63-residue fragment completely abolished,
GP31 association. These observations are in agreement with the
transfection data. The above results strongly suggest that the
binding site of Phd for GJy is in the N terminus. As a negative
control, in the absence of Phd sequences GST alone did not
bring down any Gf3y; thus, the binding of Gfry is specific for
Phd and not for GST or for the Sepharose beads.
The interaction of Phd with Gfry was further studied by a
series of SPR measurements on the Pharmacia Biosensor
BIAcore instrument (31, 32). In these experiments, the Gf3y
complex from bovine retina was immobilized on the sensor
chip and solutions of purified GST-Phd fusion proteins were
introduced to the activated surface in a flow cell. Fig. 5
( RU )
demonstrates the increase of the SPR signal during the
injections of wild-type and mutant forms of Phd fusion pro-
teins into the flow cell with immobilized Gf3y. Wild-type Phd,
the N-terminal 63-amino acid residue fragment (Phdl-63),
and the tryptophan-to-valine (PhdW29V) mutant bound Gf3y
under these conditions, while no binding was detected with the
C-terminal fragment of Phd (Phdll2-245) or with the 63-
residue fragment bearing the substitution (PhdW29V1-63)
(data not shown). In the control experiment, no binding was
detected with OST. Both association and dissociation of Phd
were slow-the apparent rate constants for wild-type Phd were
measured as ka = 3.8 ± 0.5 x 103 M-1-S (n = 2) and kd =
3.2 ± 0.1 X 10-4 (n = 2). The apparent equilibrium constant
KD is 86 + 4 nM, which was determined as the ratio between
kd and ka. Phdl-63 fragment bound to G3,3ywith -3-fold lower
affinity than the full-sized protein (KD = 318 ± 21 nM) with
both reduced association (ka = 1.8 ± 0.5 x 103 M-'s_1; n =
3) and increased dissociation rate (kd = 5.6 ± 0.2 x 10-4; n =
3) apparently caused by the truncation. The PhdW29V mutant
showed very low affinity to Gf3y primarily because of a more
rapid dissociation. At the highest concentration of this mutant
(30 ,uM), the binding reached steady state at relatively low
levels (150 RU); therefore, it was difficult to achieve reliable
quantitative determination of the binding constants. The KD
was estimated as 1-5 ,uM,withka- 100-1000 M-l s-1 andkd >
3 x 10-3 (n = 3). The data obtained with the SPR biosensor
are in good agreement with estimates made by both affinity
chromatography on the glutathione Sepharose beads and COS
cell cotransfection assay.
DISCUSSION
In summary, a series of specific deletion and substitution
mutations were made in bovine Phd. Three types of assays
were used to address its interaction with Gf3y. In the cotrans-
fection assay, it was shown that the N-terminal 63 amino acid
residues were required for inhibition of Go3y-mediated PLCI32
activation (Fig. 1). Without the N terminus, Phd lost its ability
to inhibit. Substitution of the sole tryptophan residue (Trp-29)
in the N-terminal region for a valine residue severely impaired
Phd inhibitory function. When the fragment of Phd consisting
of the first 63 residues was expressed as a GST fusion protein,
it was able to bind to G,3y in vitro when tested by both affinity
chromatography and SPR biosensor technology. The trypto-
phan-to-valine substitution drastically decreased Phd binding
to GP3y. Data gathered in all three assays agreed very well and
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FIG. 5. Analysis of binding of GST-Phd fusion proteins and Gf3y using a BIAcore biosensor. Solutions of purified recombinant Phd were
introduced by flow across the surface of the sensor chip SA5 (Pharmacia Biosensor) with immobilized Gf3'y complex. Increase of the SPR signal
(y axis) during the time of injection (x axis) indicates the binding of Phd. Concentration of the Phd preparations was 3 JLM for GST-Phd and
GST-Phdl-63, 5 ,uM for GST-PhdW29V, and 9 ,uM for GST. Data were collected from independent sensor chip channels on which 2000 ± 200
RU of Gf3y was immobilized. A representative of n independent experiments is shown (see text for values of n). Binding curves were analyzed after
subtracting the background (injection of GST). The resulting curve for GST-Phdl-63 was multiplied by a factor of 2 in order to normalize with
the full-size GST-Phd fusion protein, which is twice the size of the truncated form.
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the results indicate that the primary Gf3y binding site of Phd
is located in the first 63 residues and the 11-amino acid
conserved stretch, which includes the critical tryptophan res-
idue, plays an important role.
Our data do not exclude the possibility that other regions of
Phd also contribute to Gf3y binding. Phdl-63 inhibited PLC,32
activation moderately while Phdl-120 and Phdl-245 were
more efficient. The GST-Phdl-63 fusion protein retained
much less of the Gf3y proteins and showed lower affinity for
Gf3y than the intact molecule. Although the C terminus could
neither inhibit nor bind GP3y, it may still play a role in
formation and stabilization of the tertiary structure of Phd that
enables Phd to interact more efficiently with Gf3y. Further-
more, the phosphorylation site that regulates Phd binding to
Gf-y has been shown to be at Ser-73 (18). Modifications at this
site could lead to changes in the configuration of the protein
and thus act to prevent Gj3y interaction. Alternatively, the
phosphorylation may have a local steric or electrosteric effect
on Gj3y binding. In any event, measurements of Phd-Gf3y
binding suggest that it represents a high-affinity interaction.
The N-terminal region of Phd is important for binding activity.
However, it is not clear how effective Phd would be as a
competitive inhibitor of the GDP-bound form of the a subunit
of transducin since in vivo this would depend a great deal on
relative local concentrations in the photoreceptor cells. The in
vitro binding system may allow us to design molecules that
could be introduced into transgenic animals to test this
hypothesis.
While this manuscript was in preparation, Hawes et al. (33)
reported that the first 105 amino acid residues in human retinal
Phd contain GP3'y binding activity. Our data agree with and
confirm their results. We further identify the first 63-amino
acid residue fragment as required for binding and show that the
sole tryptophan residue makes an important contribution.
Recently, the rat Phd-like protein, an ethanol-responsive
potential modulator of G-protein function (27), was coex-
pressed with G,3y and PLC,B2 in COS-7 cells and it was found
to inhibit GI3y-mediated PLCI32 activation. The nature of the
regions involved in interaction with Gfry and whether they
share homology with those in Phd remain to be investigated.
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